Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31031847 | 1.00 | KMT2A (0.63) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL571382 | 0.92 | KMT2A (0.67) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL19402658 | 0.91 | KMT2A (0.54) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL31652687 | 0.91 | KMT2A (0.70) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL27928895 | 0.91 | KMT2A (0.70) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL12833414 | 0.90 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL26900694 | 0.89 | KMT2A (0.57) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL6364079 | 0.89 | KMT2A (0.70) | KMT2AEPHX2CASP3 | |
| SCHEMBL7402295 | 0.88 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL13472009 | 0.87 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185713-A2 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | Pfizer Products Inc. (US) | 2010-05-19 | — | — | EP | claimed |
| WO-2009019561-A2 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-12 | — | — | WO | claimed |
| EP-1893767-A1 | PROCESS FOR PRODUCING ATORVASTATIN, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006134482-A1 | PROCESS FOR PRODUCING ATORVASTATIN, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF | PFIZER INC. (US) | 2006-12-21 | — | — | WO | claimed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-3538539-B1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12377159-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025072637-A1 | OXYGENATED HETEROCYCLIC LSD-1 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| WO-2006134482-A1 | PROCESS FOR PRODUCING ATORVASTATIN, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF | PFIZER INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006066183-A2 | NOVEL SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-7030118-B2 | Pyrrolotriazinone compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1519729-A1 | PYRROLOTRIAZINONE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003099286-A1 | PYRROLOTRIAZINONE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-1999054321-A1 | SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | KMT2A 3783/4885EPHX2 1658/4885CASP3 1633/4885 |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | CCNB1, NUMA1, CCNA1 | KMT2A 325/4885EPHX2 4363/4885CASP3 357/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | KMT2A 1659/4885EPHX2 3947/4885CASP3 3888/4885 |
| US-12377159-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | KMT2A 4548/4885EPHX2 2443/4885CASP3 4393/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | KMT2A 1569/4885EPHX2 4321/4885CASP3 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.